Research Highlights:

• An artificial intelligence (AI) tool detected structural heart problems using a single-lead ECG captured by the electrical heart sensor on the back and digital crown of a smartwatch.
• The AI algorithm was tested on single-lead ECGs taken on a smartwatch in a group of 600 adults. The algorithm accurately identified structural heart diseases such as weakened pumping ability, damaged valves or thickened heart muscle.
• Smartwatches with single-lead ECG sensors paired with an AI tool such as the one developed for this study could help make screening for structural heart disease easier and more accessible to everyone.
• Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as full manuscripts in a peer-reviewed scientific journal.

DALLAS - November 3, 2025 (NEWMEDIAWIRE) - An artificial intelligence (AI) algorithm paired with the single-lead electrocardiogram (ECG) sensors on a smartwatch accurately diagnosed structural heart diseases, such as weakened pumping ability, damaged valves or thickened heart muscle, according to a preliminary study to be presented at the American Heart Association’s Scientific Sessions 2025. The meeting, Nov. 7-10, in New Orleans, is a premier global exchange of the latest scientific advancements, research, and evidence-based clinical practice updates in cardiovascular science.

Researchers said this is the first prospective study to show that an AI algorithm can detect multiple structural heart diseases based on measures taken from a single-lead ECG sensor on the back and digital crown of a smartwatch.

“Millions of people wear smartwatches, and they are currently mainly used to detect heart rhythm problems such as atrial fibrillation. Structural heart diseases, on the other hand, are usually found with an echocardiogram, an advanced ultrasound imaging test of the heart that requires special equipment and isn’t widely available for routine screening,” said study author Arya Aminorroaya, M.D., M.P.H., an internal medicine resident at Yale New Haven Hospital and a research affiliate at the Cardiovascular Data Science (CarDS) Lab at Yale School of Medicine in New Haven, Connecticut. “In our study, we explored whether the same smartwatches people wear every day could also help find these hidden structural heart diseases earlier, before they progress to serious complications or cardiac events.”

Researchers developed the AI algorithm using more than 266,000 12-lead ECG recordings from more than 110,000 adults. Based on this library of data, they developed an algorithm to identify structural heart disease from a single-lead ECG that can be obtained using smartwatch sensors. For this purpose, researchers isolated only one of the 12 leads of the ECG, which resembles the single-lead ECG on smartwatches. They also accounted for random interference in ECG signaling or “noise” that could arise during the recording of a single-lead ECG using real-world smartwatches. The AI model was then externally validated using data from people seeking care at community hospitals, as well as data from a population-based study from Brazil. Then, they prospectively recruited 600 participants who underwent 30-second, single-lead ECGs using a smartwatch to gauge the algorithm’s accuracy in a real-world setting.

The analysis found:

• Using single-lead ECGs obtained from hospital equipment, the AI model was very effective at distinguishing people with and without structural heart disease, scoring 92% on a standard performance scale (where 100% is perfect).
• Among the 600 participants with the single-lead ECGs obtained from a smartwatch, the AI model maintained high performance at 88% for detecting structural heart disease.
• The AI algorithm accurately identified most people with heart disease (86% sensitivity) and was highly accurate in ruling out heart disease (99% negative predictive value).

“On its own, a single-lead ECG is limited; it can’t replace a 12-lead ECG test available in health care settings. However, with AI, it becomes powerful enough to screen for important heart conditions,” said Rohan Khera, M.D., M.S., the senior author of the study, and the director of the CarDS Lab. “This could make early screening for structural heart disease possible on a large scale, using devices many people already own.”

Study background, details, and design:

• Researchers used a database of 266,054 ECGs from 110,006 patients who received testing and treatment at Yale New Haven Hospital between 2015 and 2023 to develop an AI-ECG algorithm to detect structural heart disease from single-lead ECGs.
• The algorithm was matched to heart ultrasound scans to see whether they had structural heart disease or not.
• The AI model was then validated in 44,591 adults seeking care at four community hospitals and 3,014 participants from the population-based ELSA-Brasil study. The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) gathers important information about how chronic diseases develop and progress, focusing mainly on cardiovascular diseases and diabetes.
• To get the AI model ready for interpreting signals from real-world, single-lead ECGs, researchers added some “noise” - think of it like fuzz or static - into the mix for model training. This little tweak helped the AI become resilient and more reliable when dealing with less-than-perfect signals, making it better at spotting structural heart disease even when the data isn’t crystal clear.
• During the real-world prospective study, 600 patients wore the same type of smartwatch with a single-lead ECG sensor for 30 seconds on the same day they were getting a heart ultrasound.
• The median age of the participants was 62 years, and about half were women, 44% were non-Hispanic white, 15% non-Hispanic Black, 7% Hispanic, 1% Asian and 33% others. About 5% were found to have structural heart disease on the heart ultrasound.

Study limitations include a small number of patients with the actual disease in the prospective study and the number of false positive results.

“We plan to evaluate the AI tool in broader settings and explore how it could be integrated into community-based heart disease screening programs to assess its potential impact on improving preventive care,” Aminorroaya said.

Co-authors, disclosures, and funding sources are listed in the abstract.

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantees as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed; rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.

Additional Resources:

• Multimedia is available on the right column of the release link.
• Link to abstract, and the American Heart Association’s Scientific Sessions 2025 Online Program Planner
• American Heart Association statement news release: Equitable access to digital technologies may help improve cardiovascular health (April 2025)
• American Heart Association news release: Novel algorithm on wearable devices can detect irregular heartbeat, may prompt early care (Nov. 2021)
• About Scientific Sessions 2025
• For more news at the American Heart Association’s Scientific Sessions 2025, follow us on X @HeartNews #AHA25

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.

For Media Inquiries and American Heart Association Expert Perspective: American Heart Association Communications & Media Relations: 214-706-1173, ahacommunications@heart.org

Karen Astle: Karen.Astle@heart.org

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org

View the original release on www.newmediawire.com